Stay updated with breaking news from Mdma Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A drug application for psychedelic-assisted therapies has been filed for FDA approval. Marine Corps veteran Juliana Mercer shares the benefits of the treatment, with doctors also weighing in.
ATMA Journey Centers Inc. ("ATMA"), a Canadian company with a primary focus on advancing psychedelic-assisted therapy, is pleased to announce its collaboration with Dr. Scott Shannon to prepare practitioners in training for the eagerly anticipated legalization of MDMA for MDMA-assisted therapy (MaT). Dr. Shannon will join Dr. Ben Sessa (psychiatrist and Bristol Imperial MDMA Study Academic), Mark Haden (Previous Executive Directors of MAPS Canada) and Ben Malcolm (Psychiatric Pharmacists, Spirit
In most cases, these are Schedule I substances, like MDMA and psilocybin, that the government has labeled as drugs with a high risk for abuse no current accepted medical use, but recent research has shown they can help treat severe forms of depression that other medications cannot.